Carbidopa

Carbidopa
Clinical data
Trade names	Lodosyn
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN; US FDA: Carbidopa;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Protein binding	76%
Metabolism	7 metabolites known, not metabolized extensively
Elimination half-life	2 hours
Identifiers
	IUPAC name (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid;
CAS Number	28860-95-9 ;
PubChem CID	34359;
IUPHAR/BPS	5159;
DrugBank	DB00190 ;
ChemSpider	31640 ;
UNII	KR87B45RGH;
KEGG	D00558 ;
ChEBI	CHEBI:39585 ;
ChEMBL	ChEMBL1201236 ;
CompTox Dashboard (EPA)	DTXSID4022735 ;
ECHA InfoCard	100.044.778
Chemical and physical data
Formula	C10H14N2O4
Molar mass	226.232 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	203 to 205 °C (397 to 401 °F)
	SMILES O=C(O)[C@@](NN)(Cc1cc(O)c(O)cc1)C;
	InChI InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1 ; Key:TZFNLOMSOLWIDK-JTQLQIEISA-N ;
	(what is this?) (verify)

Carbidopa (Lodosyn) is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa. This property is significant in that it allows a greater proportion of administered levodopa to cross the blood–brain barrier for central nervous system effect, instead of being peripherally metabolised into substances unable to cross said barrier.

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.

Carbidopa

Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.